Drug or technology
12 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
This is a Phase 1 registry record with no posted results; it describes a planned single-dose interventional study in a small sample (n=40) using surrogate endpoints (affect, pain catastrophizing, quantitative sensory testing) to explore mechanistic effects of psilocybin in a novel indication.
SEP 4, 2026 · PHASE EARLY PHASE 1 TRIAL
ClinicalTrials.gov
Early-phase pilot study with no results yet reported; designed to assess safety and feasibility of psilocybin in a cognitively vulnerable population.
Phase 1 trial with planned enrollment and no results reported; registry record only describes study design and intended outcomes.
AUG 14, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 trial registration with no reported results; the study is actively recruiting and outcome data are not yet available, so evidence strength cannot be assessed.
AUG 13, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
Phase 2 open-label trial with no results posted; early-stage study of psilocybin-assisted therapy still recruiting, examining safety and efficacy in a specialized population.
AUG 13, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 registry record for an ongoing open-label study with no results posted; the planned design and small sample limit inference to hypothesis-generating potential.
AUG 12, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
Early-phase interventional study (Phase 2) with small planned enrollment (n=20) assessing feasibility and safety of a novel psychedelic intervention in a specific population; results not yet reported.
AUG 12, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
This is an active Phase 2 trial registration with no results yet posted; it describes a planned study of feasibility and safety in a small cohort.